MedTrace Logo

Efficacy of a Hydrolyzed Chicken Collagen Type II in Alleviating Joint Discomfort

NCT04955353 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-07-08

No results posted yet for this study

Summary

Joint pain and disease affect more than one in four adults in the United States. We conducted a double-blind, randomized, placebo-controlled trial to investigate the efficacy of a hydrolyzed chicken collagen type II (HCII) supplement in reducing joint-related discomfort such as pain and stiffness, and in improving mobility. We enrolled adults aged 40-65y (65.5% were women) who had joint discomfort, but had no co-morbidities, and were not taking pain medications. The participants were randomized to receive either the HCII supplement (n=47) or a placebo (n=43) for eight weeks. At baseline, week 4, and week 8, we administered the Western Ontario and McMaster Universities Arthritis Index (WOMAC) survey with three additional wrist-related questions and the Visual Analog Scale for assessments of joint-related symptoms.

Conditions

  • Joint Discomfort

Interventions

DIETARY_SUPPLEMENT

AVC-H2

A total of 2.5g AVC-H2 daily (2 tablets in the morning and 2 in the evening)

DIETARY_SUPPLEMENT

Placebo

A total of 2.5g placebo daily (2 tablets in the morning and 2 in the evening)

Sponsors & Collaborators

  • BioScreen Testing Services

    collaborator UNKNOWN

  • Avicenna Nutraceutical

    lead OTHER

Principal Investigators

  • Rania Ibrahim, PhD · BioScreen Testing Services

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-16
Primary Completion
2018-02-12
Completion
2018-02-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04955353 on ClinicalTrials.gov